Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129193) titled 'A retrospective study on the treatment of hepatocellular carcinoma with different doses of bevacizumab combined with sintilimab and TACE/HAIC' on July 31.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: HenanCancerHospital
Condition:
Hepatocellular carcinoma
Intervention:
Reduced-dose bevacizumab in combination with TACE and/or HAIC plus sintimab for the treatment of HCC patients:None
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2026-08-01
Target Sample Size: Reduced-dose bevacizumab in combination with TACE and/or HAIC plus sintimab for the treatmen...